Du

Medicure Reports Financial Results for Quarter Ended March 31, 2021

Monday, May 10, 2021 - 10:30pm

b'WINNIPEG, May 10, 2021 /PRNewswire/ -Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), acompany focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2021.\nRecorded total net revenue of $4.9 million during the quarter ended March 31, 2021 compared to $3.0 million for the quarter ended March 31, 2020 and;\nRecorded total net revenue from the sale of AGGRASTAT of $2.6 million during the quarter ended March 31, 2021 compared to $2.7 million for the quarter ended March 31, 2020 and;\nDiversified product portfolio with revenues from the Marley Drug business of $2.1 million and ZYPITAMAGrevenues of $161,000 during the quarter ended March 31, 2021 and;\nAdjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended March 31, 2021 was $31,000 compared to adjusted EBITDA of negative $1.3 million for the quarter ended March 31, 2020 and;\nNet loss for the quarter ended March 31, 2021 was $1.0 million compared to $1.5 million for the quarter ended March 31, 2020.\nAGGRASTAT revenues were consistent when compared to the same period in the previous year.

Key Points: 
  • b'WINNIPEG, May 10, 2021 /PRNewswire/ -Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), acompany focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2021.\nRecorded total net revenue of $4.9 million during the quarter ended March 31, 2021 compared to $3.0 million for the quarter ended March 31, 2020 and;\nRecorded total net revenue from the sale of AGGRASTAT of $2.6 million during the quarter ended March 31, 2021 compared to $2.7 million for the quarter ended March 31, 2020 and;\nDiversified product portfolio with revenues from the Marley Drug business of $2.1 million and ZYPITAMAGrevenues of $161,000 during the quarter ended March 31, 2021 and;\nAdjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended March 31, 2021 was $31,000 compared to adjusted EBITDA of negative $1.3 million for the quarter ended March 31, 2020 and;\nNet loss for the quarter ended March 31, 2021 was $1.0 million compared to $1.5 million for the quarter ended March 31, 2020.\nAGGRASTAT revenues were consistent when compared to the same period in the previous year.
  • The Company continues to maintain the majority of patient market share in the GPI IIb/IIIa drug class.\nZYPITAMAG contributed $161,000 of revenue for the quarter ended March 31, 2021 compared to $163,000 for the quarter ended March 31, 2020.
  • The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three months ended March 31, 2021 and 2020 results prepared using IFRS, do not have any standardized meaning according to IFRS.
  • Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.

CEVA, Inc. Announces First Quarter 2021 Financial Results

Monday, May 10, 2021 - 12:00pm

b'ROCKVILLE, Md., May 10, 2021 /PRNewswire/ --CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies,today announced its financial results for the first quarter ended March 31, 2021.\nTotal revenue for the first quarter of 2021 was $25.4 million, an 8% increase year-over-year.\nTotal revenue for the first quarter of 2021 was $25.4 million, an 8% increase compared to $23.6 million reported for the first quarter of 2020.

Key Points: 
  • b'ROCKVILLE, Md., May 10, 2021 /PRNewswire/ --CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies,today announced its financial results for the first quarter ended March 31, 2021.\nTotal revenue for the first quarter of 2021 was $25.4 million, an 8% increase year-over-year.\nTotal revenue for the first quarter of 2021 was $25.4 million, an 8% increase compared to $23.6 million reported for the first quarter of 2020.
  • First quarter 2021 licensing and related revenue was $14.4 million, a decrease of 1% when compared to $14.5 million reported for the same quarter a year ago.
  • Royalty revenue for the first quarter of 2021 was $11.0 million, an increase of 21% when compared to $9.1 million reported for the first quarter of 2020.\nEleven license agreements were completed during the quarter, out of which two were with first time customers.
  • "\nNet loss for the first quarter of 2021 was $3.6 million, as compared to a net loss of $1.2 million reported for the same period in 2020.

Sprague Resources LP Reports First Quarter 2021 Results

Thursday, May 6, 2021 - 11:00am

b'PORTSMOUTH, N.H., May 06, 2021 (GLOBE NEWSWIRE) -- Sprague Resources LP (\xe2\x80\x9cSprague\xe2\x80\x9d) (NYSE: SRLP) today reported its financial results for the first quarter ended March\xc2\xa031, 2021.\nNet sales were $1,036.1 million for the first quarter of 2021, compared to net sales of $959.9 million for the first quarter of 2020.\nGAAP net income was $48.8 million for the first quarter of 2021, compared to net income of $46.7 million for the first quarter of 2020.\nAdjusted gross margin* was $106.2 million for the first quarter of 2021, compared to adjusted gross margin of $83.1 million for the first quarter of 2020.\nAdjusted EBITDA* was $61.8 million for the first quarter of 2021, compared to adjusted EBITDA of $42.4 million for the first quarter of 2020.\n\xe2\x80\x9cSprague\xe2\x80\x99s Adjusted EBITDA increased by 46% over last year as our Refined Products and Natural Gas businesses captured opportunities associated with the modestly colder weather.

Key Points: 
  • b'PORTSMOUTH, N.H., May 06, 2021 (GLOBE NEWSWIRE) -- Sprague Resources LP (\xe2\x80\x9cSprague\xe2\x80\x9d) (NYSE: SRLP) today reported its financial results for the first quarter ended March\xc2\xa031, 2021.\nNet sales were $1,036.1 million for the first quarter of 2021, compared to net sales of $959.9 million for the first quarter of 2020.\nGAAP net income was $48.8 million for the first quarter of 2021, compared to net income of $46.7 million for the first quarter of 2020.\nAdjusted gross margin* was $106.2 million for the first quarter of 2021, compared to adjusted gross margin of $83.1 million for the first quarter of 2020.\nAdjusted EBITDA* was $61.8 million for the first quarter of 2021, compared to adjusted EBITDA of $42.4 million for the first quarter of 2020.\n\xe2\x80\x9cSprague\xe2\x80\x99s Adjusted EBITDA increased by 46% over last year as our Refined Products and Natural Gas businesses captured opportunities associated with the modestly colder weather.
  • The distribution will be paid on May\xc2\xa010, 2021 to unitholders of record as of the close of business on May\xc2\xa04, 2021.\nManagement will review Sprague\xe2\x80\x99s first quarter 2021 financial results in a teleconference call for analysts and investors today, May\xc2\xa06, 2021 at 1:00 PM EST.\nParticipants can dial in up to 30 minutes prior to the start of the call.
  • These are not all of the important factors that could cause actual results to differ materially from those expressed in forward looking statements.
  • Sprague undertakes no obligation and does not intend to update any forward-looking statements to reflect new information or future events.

Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance

Wednesday, May 5, 2021 - 12:00pm

Total net product revenue for the quarter included $23.8 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue and $9.8 million of Epicel (cultured epidermal autografts) net revenue, compared to $20.3 million of MACI net revenue and $6.4 million of Epicel net revenue, respectively, in the first quarter of 2020.

Key Points: 
  • Total net product revenue for the quarter included $23.8 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue and $9.8 million of Epicel (cultured epidermal autografts) net revenue, compared to $20.3 million of MACI net revenue and $6.4 million of Epicel net revenue, respectively, in the first quarter of 2020.
  • A slide presentation with highlights from today\xe2\x80\x99s conference call will be available on the webcast and in the Investor Relations section of the Vericel website.
  • To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation\xe2\x80\x99s first quarter 2021 investor conference call.
  • Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release.

Gaming Innovation Group reports Q1 2021

Wednesday, May 5, 2021 - 7:18am

b'OSLO, Norway, May 5, 2021 /PRNewswire/ -- Gaming Innovation Group Inc. (GiG) reports Q1 2021 revenues of 18.3 million and an EBITDA of 4.6 million.\n"The first quarter of 2021 is a strong start to the year and another positive step forward for Gaming Innovation Group, with strong results driven from the work and strategic initiatives pushed through in the last 12 months.

Key Points: 
  • b'OSLO, Norway, May 5, 2021 /PRNewswire/ -- Gaming Innovation Group Inc. (GiG) reports Q1 2021 revenues of 18.3 million and an EBITDA of 4.6 million.\n"The first quarter of 2021 is a strong start to the year and another positive step forward for Gaming Innovation Group, with strong results driven from the work and strategic initiatives pushed through in the last 12 months.
  • We are happy with the overall progress, and look forward to continuing to grow towards our long term objectives", says Richard Brown, CEO of GiG.\nRevenues in Media Services at all-time high of 10.0m (8.2) in Q1 2021, an increase of 23%, EBITDA was 4.6m (4.5)\nEBITDA for Sports Betting Services was -0.4m (-1.7) an improvement of 1.3m, driven by operating expenses reduction of 75%\nPositive EBIT of 1.3m (-4.7) in Q1 2021, an improvement of 6.0\nTwo new agreements were signed for Platform Services in the first quarter, with one new agreement signed so far in the second quarter\nCompleted the development for five new brands, whereof three are live on the platform and the remaining pending the client\'s decision to launch, expected in Q2 2021\nMedia Services continued its positive development in the quarter, with all-time high revenues and FTDs up 56% YoY, and 31% QoQ\nSigned an agreement for the provision of GiG\'s iGaming platform to power a new online casino for the European market, operating on its own license\nOne brand went live early May, two additional brands are ready to go live, and the remaining integration pipeline stands at 10 brands as of today\nGiG Media delivered another all-time high in revenues in April, up 10% on Q1 2021 average with another all-time high in FTD\'s referred\nCEO Richard Brown will present the Q1 2021 results today via livestream at 10:00 CET.
  • The presentation will be followed by a Q&A-session, and investors, analysts and journalists are welcome to participate.
  • The presentation will be given in English.\n'

Gaming Innovation Group reports Q1 2021

Wednesday, May 5, 2021 - 7:16am

b'OSLO, Norway, May 5, 2021 /PRNewswire/ -- Gaming Innovation Group Inc. (GiG) reports Q1 2021 revenues of 18.3 million and an EBITDA of 4.6 million.\n"The first quarter of 2021 is a strong start to the year and another positive step forward for Gaming Innovation Group, with strong results driven from the work and strategic initiatives pushed through in the last 12 months.

Key Points: 
  • b'OSLO, Norway, May 5, 2021 /PRNewswire/ -- Gaming Innovation Group Inc. (GiG) reports Q1 2021 revenues of 18.3 million and an EBITDA of 4.6 million.\n"The first quarter of 2021 is a strong start to the year and another positive step forward for Gaming Innovation Group, with strong results driven from the work and strategic initiatives pushed through in the last 12 months.
  • We are happy with the overall progress, and look forward to continuing to grow towards our long term objectives", says Richard Brown, CEO of GiG.\nRevenues in Media Services at all-time high of 10.0m (8.2) in Q1 2021, an increase of 23%, EBITDA was 4.6m (4.5)\nEBITDA for Sports Betting Services was -0.4m (-1.7) an improvement of 1.3m, driven by operating expenses reduction of 75%\nPositive EBIT of 1.3m (-4.7) in Q1 2021, an improvement of 6.0\nTwo new agreements were signed for Platform Services in the first quarter, with one new agreement signed so far in the second quarter\nCompleted the development for five new brands, whereof three are live on the platform and the remaining pending the client\'s decision to launch, expected in Q2 2021\nMedia Services continued its positive development in the quarter, with all-time high revenues and FTDs up 56% YoY, and 31% QoQ\nSigned an agreement for the provision of GiG\'s iGaming platform to power a new online casino for the European market, operating on its own license\nOne brand went live early May, two additional brands are ready to go live, and the remaining integration pipeline stands at 10 brands as of today\nGiG Media delivered another all-time high in revenues in April, up 10% on Q1 2021 average with another all-time high in FTD\'s referred\nCEO Richard Brown will present the Q1 2021 results today via livestream at 10:00 CET.
  • The presentation will be followed by a Q&A-session, and investors, analysts and journalists are welcome to participate.
  • The presentation will be given in English.\n'

Russel Metals Announces 2021 First Quarter Results

Tuesday, May 4, 2021 - 10:00pm

Revenues of $885 million were higher than the $815 million experienced in first quarter of 2020 and the $671 million in the fourth quarter of 2020.

Key Points: 
  • Revenues of $885 million were higher than the $815 million experienced in first quarter of 2020 and the $671 million in the fourth quarter of 2020.
  • Our gross margins improved to 28.8% compared to 18.7% in the same quarter of 2020 and 20.8% in the fourth quarter of 2020.
  • Our Adjusted EBITDA, which equaled EBITDA,for the quarter was $129 million compared to Adjusted EBITDA of $39 million in the same quarter of 2020 and $41 million in the fourth quarter of 2020.\nDuring the 2021 first quarter, EBITDA was reduced by $2 million related to the mark-to-market of non-cash stock-based compensation as compared to $4 million in the 2020 fourth quarter.
  • The quarter\'s results include $3 million in federal government wage subsidies as compared to $8 million in the 2020 fourth quarter.\nEach of our segments generated a substantial improvement in operating profit for the first quarter of 2021 versus the fourth quarter of 2020.

Neuronetics Reports First Quarter 2021 Financial and Operating Results

Tuesday, May 4, 2021 - 12:00pm

NeuroStar Advanced Therapy System revenue for the first quarter of 2021 was $1.8 million, a decrease of 32% over first quarter 2020 revenue of $2.6 million.

Key Points: 
  • NeuroStar Advanced Therapy System revenue for the first quarter of 2021 was $1.8 million, a decrease of 32% over first quarter 2020 revenue of $2.6 million.
  • For the three months ended March 31, 2021 and 2020, the Company sold 23 and 38 systems, respectively, during each period.\nU.S.
  • treatment session revenue for the first quarter of 2021 was $9.6 million, an increase of 18% over the first quarter of 2020 of $8.2 million.
  • See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss.\nCash and cash equivalents were $121.3 million as of\xc2\xa0March\xc2\xa031, 2021.

Stella-Jones Reports First Quarter Results

Monday, May 3, 2021 - 12:00pm

EBITDA rose to $99 million, up 57%, compared to $63 million reported in the first quarter of 2020.

Key Points: 
  • EBITDA rose to $99 million, up 57%, compared to $63 million reported in the first quarter of 2020.
  • During the quarter, the Company, through its wholly-owned U.S subsidiary (\xe2\x80\x9cU.S.
  • These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events.
  • As a result, readers are advised that actual results may differ from expected results.

Harborside Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

Monday, April 26, 2021 - 12:15pm

During Q4 2020, Harborside generated total gross revenues of approximately $13.1 million.

Key Points: 
  • During Q4 2020, Harborside generated total gross revenues of approximately $13.1 million.
  • For FY 2020, wholesale gross revenues were approximately $21.4 million, an approximately 105% increase from the approximately $10.4 million of wholesale gross revenues achieved in FY 2019.
  • For FY 2020, retail revenues were approximately $42.0 million, an increase of approximately 9.0% as compared to the approximately $38.6 million in retail revenues in FY 2019.
  • See "Non-IFRS Financial Measures, Reconciliation, and Discussion".\nAs of December 31, 2020, Harborside had total current assets of approximately $19.8 million, including cash of approximately $10.5 million.